当前位置： SCI文献检索 > CANCER期刊下所有文献 > Logistic regression model of fotemustine toxicity combining independent phase II studies.

Logistic regression model of fotemustine toxicity combining independent phase II studies.

Abstract：

BACKGROUND:To optimize fotemustine chemotherapy, the authors considered how to combine independent Phase II trials to predict the risk of first occurrence of severe toxicity as a function of initial patient characteristics. METHODS:Clinical data from six Phase II trials were collected. Of the 478 patients enrolled 442 (male/female, 259/183; age range, 15-81 years) were evaluable for toxicity (1384 cycles of chemotherapy), including 221 with malignant malignant melanomas, 138 with primary brain tumors, 29 with lung carcinomas, 8 with head and neck carcinomas, and 46 with miscellaneous cancers. The influence of age, sex, performance status, type of tumor, number and location of metastases, and previous treatment by chemotherapy and/or radiotherapy was studied. The logistic regression method was applied to predict occurrence of leukopenia, thrombocytopenia, anemia, digestive tract, and/or hepatic toxicity. RESULTS:Univariate analysis showed that predictive factors for hematologic toxicity were age (> 50 years), type of tumor (brain < melanoma < others), number of metastatic sites (> 3), location of metastases (nonvisceral), and previous chemotherapy. Performance status and previous radiotherapy did not affect the toxicity of fotemustine Nausea and vomiting were predictable based on the type of tumor (head and neck < lung < brain < melanoma < others), the number of metastatic sites (> three) and visceral metastases. Hepatic disorders occurred preferentially in patients with hepatic metastases and more than three metastatic sites. Individual risk of hematologic and hepatic toxicity for patients with melanoma and primary brain tumors was predicted using logistic regression models. CONCLUSIONS:By combining clinical data from independent Phase II trials, the logistic model developed could predict the probability of fotemustine hematologic and hepatic toxicity.

journal_name

Cancer

journal_title

Cancer

authors

Raymond E,Haon C,Boaziz C,Coste M

subject

Has Abstract

pub_date

1996-11-01 00:00:00

pages

1980-7

issue

eissn

0008-543X

issn

1097-0142

pii

10.1002/(SICI)1097-0142(19961101)78:9<1980::AID-CN

journal_volume

pub_type

杂志文章,meta分析

在线工具

Logistic regression model of fotemustine toxicity combining independent phase II studies.